SCHEMBL24006105

SCHEMBL24006105

CC(C)Cc1cc2cccnc2o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.36
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
POLB P06746 2/20 0.34
ALDH1A1 P00352 4/20 0.34
RAB9A P51151 3/20 0.34
CYP2A6 P11509 1/20 0.33
HTT P42858 3/20 0.33
MAPT P10636 2/20 0.32
TSHR P16473 2/20 0.32
MAPK1 P28482 1/20 0.32
TP53 P04637 3/20 0.32
KDM4E B2RXH2 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 2/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CCR1 P32246 2/20 0.31
CCR8 P51685 2/20 0.31
GMNN O75496 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9277705 0.81 SGMS2 (0.36) ELANELMNAPOLBALDH1A1RAB9A
SCHEMBL20181538 0.78 TLR8 (0.50) ELANELMNAALDH1A1CYP2A6HTT
SCHEMBL8570708 0.77 NR4A2 (0.35) LMNAL3MBTL1POLBALDH1A1RAB9A
SCHEMBL2624387 0.75 CCR1 (0.37) LMNAL3MBTL1POLBALDH1A1RAB9A
SCHEMBL5962355 0.72 LOXL2 (0.58) LMNAL3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL128666 0.71 ALDH1A1 (0.42) LMNAL3MBTL1POLBALDH1A1RAB9A
SCHEMBL3564812 0.68 PSMD14 (0.34) LMNAPOLBALDH1A1RAB9ACYP2A6
SCHEMBL15966361 0.67 HTT (0.42) LMNAPOLBALDH1A1RAB9AHTT
SCHEMBL16901678 0.67 ALDH1A1 (0.42) LMNAPOLBALDH1A1RAB9AHTT
SCHEMBL18660657 0.67 HTT (0.38) LMNAL3MBTL1POLBALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED 2021-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS BCL2, BCL2L2, BCL2L1 ELANE 2865/4885LMNA 1095/4885L3MBTL1 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.